Anticoagulation Therapy with Apixaban

Introduction to Apixaban Dosing

Apixaban is an anticoagulant that requires consideration of pharmacokinetic interactions, particularly with strong dual inhibitors of CYP3A4 and P-glycoprotein, which can increase bleeding risk 1
The European Heart Rhythm Association recommends apixaban 2.5 mg twice daily for patients with at least two of the following: age ≥80 years, weight ≤60 kg, or serum creatinine ≥133 μmol/L (1.5 mg/dL) 2
The American College of Chest Physicians and the American Heart Association recommend dose reduction (2.5 mg twice daily) for patients with at least two of: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 3, 4, 5, 6, 7, 8, 9

For patients meeting two dose-reduction criteria, such as age ≥80 years and renal impairment, the recommended dose of apixaban is 2.5 mg twice daily 2
Severe renal impairment and active liver disease are considerations for apixaban dosing, as recommended by the National Comprehensive Cancer Network and the European Society of Cardiology 1, 10, 11
Patients with severe renal impairment (CrCl <15 mL/min) should avoid apixaban, and those with CrCl 15-30 mL/min should use it with caution, as supported by the National Comprehensive Cancer Network and the European Society of Cardiology 10, 11

The American College of Cardiology recommends an initial dose of 10 mg twice daily for the first 7 days when switching from enoxaparin to apixaban, followed by 5 mg twice daily for continued treatment 12
The National Comprehensive Cancer Network recommends starting apixaban at the time the next scheduled dose of enoxaparin would have been due, without an overlap period with parenteral anticoagulation 13

For extended secondary prevention of VTE, consider reducing the dose to 2.5 mg twice daily after ≥6 months of initial therapy, as recommended by the American College of Cardiology 12
Apixaban demonstrates superior efficacy to enoxaparin in preventing VTE after hip and knee replacement, with a relative risk of 0.36 and 0.62 respectively, as documented by the American College of Chest Physicians 14

Cancer patients may prefer low molecular weight heparin (LMWH) over apixaban, though apixaban is an acceptable alternative, as recommended by the National Comprehensive Cancer Network 13, 15, 16
Apixaban is not recommended during pregnancy or lactation, as stated by the American College of Chest Physicians and the American Heart Association 15, 16, 17, 18

Patients on apixaban should have regular assessment of renal function at least yearly, with more frequent monitoring in high-risk patients, according to the European Society of Cardiology and the American College of Cardiology 19
Immediate renal function assessment is required during acute illness, dehydration, congestive heart failure exacerbation, infections, acute inflammatory disorders, and hospitalization, as stated by the European Society of Cardiology 19
Patients on apixaban should be monitored for bleeding signs, such as unexplained bruising, blood in urine or stool, and unusual headaches or dizziness, as recommended by the European Heart Journal 20
The risk of major bleeding occurs in approximately 0.6-2.13% of patients per year, according to the American College of Chest Physicians and the American Heart Association, with a lower rate of 2.13% vs 3.09% per year in some studies 14, 3

Strong dual inhibitors of CYP3A4 and P-gp may require alternative medication or a 25% reduction in apixaban dose 21
Moderate inhibitors of CYP3A4 or P-gp may require a 25% reduction in apixaban dose 21
The concurrent use of apixaban with antiplatelet agents, NSAIDs, SSRIs, or SNRIs increases bleeding risk, as reported by the American College of Chest Physicians and the European Heart Journal 22, 7, 20

Patients with impaired renal function may require longer interruption periods of apixaban before surgery, as suggested by the American College of Chest Physicians 23
In urgent surgical situations, consider measuring apixaban levels with anti-factor Xa assays calibrated for apixaban, as recommended by the American College of Chest Physicians 23
For low bleeding risk procedures, interrupt apixaban 24 hours before procedure, and for high bleeding risk procedures, interrupt apixaban 3 days before procedure 24
Resume apixaban at least 6 hours after procedure completion if hemostasis is achieved 24